Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Stock Report

Market Cap: US$5.8b

Ionis Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Ionis Pharmaceuticals's earnings have been declining at an average annual rate of -38.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 5.4% per year.

Key information

-38.3%

Earnings growth rate

-37.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-5.4%
Return on equity-54.2%
Net Margin-44.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Dec 23

Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Dec 23
Investors Don't See Light At End Of Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Tunnel

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 01
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Revenue & Expenses Breakdown

How Ionis Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:IONS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24803-3592303
30 Jun 24813-3662390
31 Mar 24777-3852200
31 Dec 23788-3662130
30 Sep 23615-409210586
30 Jun 23631-3091740
31 Mar 23576-3291620
31 Dec 22587-2701500
30 Sep 2287571410
30 Jun 22849-281370
31 Mar 22841-41480
31 Dec 21810-291860
30 Sep 21661-6082070
30 Jun 21688-5502450
31 Mar 21708-4952720
31 Dec 20729-4443540
30 Sep 20933942990
30 Jun 209401452900
31 Mar 209591692930
31 Dec 191,1232812870
30 Sep 198214332690
30 Jun 197994022780
31 Mar 197523662690
31 Dec 186002772450
30 Sep 18575-412240
30 Jun 18548-381820
31 Mar 1854391380
31 Dec 17514191080
30 Sep 1750742810
30 Jun 1749952640
31 Mar 17426-15520
31 Dec 16373-60490
30 Sep 16238-184440
30 Jun 16176-227420
31 Mar 16258-134400
31 Dec 15284-88370
30 Sep 1531714310
30 Jun 1531223270
31 Mar 15249-24230
31 Dec 14214-39200
30 Sep 14172-94180
30 Jun 14151-92170
31 Mar 14132-90160
31 Dec 13147-61150

Quality Earnings: IONS is currently unprofitable.

Growing Profit Margin: IONS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IONS is unprofitable, and losses have increased over the past 5 years at a rate of 38.3% per year.

Accelerating Growth: Unable to compare IONS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IONS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: IONS has a negative Return on Equity (-54.16%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:55
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ionis Pharmaceuticals, Inc. is covered by 46 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
James BirchenoughBarclays